Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SPRO 
Spero Therapeutics Inc (SPRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SPRO (3-star) is a STRONG-BUY. BUY since 21 days. Profits (38.03%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $5
Year Target Price $5
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 65.97% | Avg. Invested days 48 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 164.38M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) - | Beta 1.31 | 52 Weeks Range 0.51 - 3.09 | Updated Date 06/29/2025 |
52 Weeks Range 0.51 - 3.09 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -156.48% | Operating Margin (TTM) -247.8% |
Management Effectiveness
Return on Assets (TTM) -37.21% | Return on Equity (TTM) -107.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 119729837 | Price to Sales(TTM) 3.69 |
Enterprise Value 119729837 | Price to Sales(TTM) 3.69 | ||
Enterprise Value to Revenue 4.23 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 55910600 | Shares Floating 41708779 |
Shares Outstanding 55910600 | Shares Floating 41708779 | ||
Percent Insiders 24.61 | Percent Institutions 23.25 |
Analyst Ratings
Rating 3.33 | Target Price 5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spero Therapeutics Inc
Company Overview
History and Background
Spero Therapeutics, Inc. is a biopharmaceutical company founded in 2013. It focuses on developing novel treatments for multi-drug resistant (MDR) bacterial infections. The company's evolution has centered on discovering and advancing therapies to address unmet needs in infectious diseases, particularly those resistant to existing antibiotics.
Core Business Areas
- Infectious Disease Therapeutics: Spero Therapeutics focuses on developing and commercializing therapies for bacterial infections, with a focus on multi-drug resistant organisms.
Leadership and Structure
Spero Therapeutics is led by a management team with experience in drug development and commercialization. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Tebipenem HBr: An IV carbapenem antibiotic. Tebipenem HBr is approved for treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Key Competitors: Other carbapenem antibiotics such as meropenem, imipenem/cilastatin.
Market Dynamics
Industry Overview
The pharmaceutical industry for infectious diseases is driven by the increasing prevalence of antibiotic-resistant bacteria and the need for new therapeutic options. It is characterized by high regulatory hurdles, significant R&D investments, and competition from established pharmaceutical companies.
Positioning
Spero Therapeutics is positioned as a company focused on addressing unmet needs in the treatment of multi-drug resistant bacterial infections. Its competitive advantage lies in its pipeline of novel antibiotics and its focus on addressing specific bacterial strains.
Total Addressable Market (TAM)
The global market for antibiotic resistance is expected to reach over $15 billion. Spero Therapeutics is positioned to capture a share of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Focused on addressing unmet needs in antibiotic resistance
- Novel antibiotic candidates in pipeline
- Experienced management team
Weaknesses
- Reliance on single product approval
- History of revenue losses
- Limited resources compared to larger pharmaceutical companies
Opportunities
- Expanding indications for existing products
- Developing new antibiotic candidates
- Partnerships with larger pharmaceutical companies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- PFE
- ABBV
Competitive Landscape
Spero Therapeutics competes with larger pharmaceutical companies in the antibiotics market. Spero's competitive advantage lies in its novel approach to addressing antibiotic resistance, while larger companies have greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by periods of clinical success and regulatory setbacks.
Future Projections: Future growth depends on successful commercialization of its approved products and further development of its pipeline.
Recent Initiatives: Recent initiatives include focusing on commercializing its approved drug and advancing its pipeline candidates.
Summary
Spero Therapeutics is a biopharmaceutical company focused on addressing unmet needs in antibiotic resistance. Its approval for Tebipenem HBr represents a significant milestone, but faces commercialization challenges. The company's future growth depends on the success of its approved products, pipeline development, and strategic partnerships. Recent financial volatility adds to the challenges facing the company. Spero's pipeline of novel antibiotics distinguishes them in a competitive market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Spero Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. Financial data is subject to change and should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spero Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-11-02 | CEO, CFO, President & Treasurer Ms. Esther P. Rajavelu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://sperotherapeutics.com |
Full time employees 32 | Website https://sperotherapeutics.com | ||
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.